RT Journal
A1 Mitka M
T1 INcentives for new antibiotics
JF JAMA
JO JAMA
YR 2012
FD August 8
VO 308
IS 6
SP 558
OP 558
DO 10.1001/jama.2012.9558
UL http://dx.doi.org/10.1001/jama.2012.9558
AB 
The legislation (S 3187; http://tinyurl.com/7kz57hk) primarily requires drug and device manufacturers to pay user fees to fund the FDA's approval process for drugs and medical devices. But some of the fees are earmarked to bolster the agency's safety oversight and to pay for other programs, such as creating incentives for antibiotic development.